


US Immunization Safety; CDC monitoring, assessment and response

Michael Bell, MD
Division of Healthcare Quality Promotion
Centers for Disease Control and Prevention

No conflicts of interest to declare.
The findings in this report are those of the author(s) and do not necessarily represent the official position the Centers for Disease Control and Prevention.


Primary U.S. Dept. of Health and Human Services organizations engaged in vaccine safety activities



Rationale for post-licensure vaccine safety monitoring

- Safety standards for vaccines are high
- Pre-licensure clinical trials are typically not designed to
 - Detect rare adverse events (numbers enrolled too small)
 - Monitor vaccine safety in a real-world environment
 - Assess safety in special populations (often excluded)
 - Evaluate adverse events with delayed onset

3



CDC + FDA Vaccine safety monitoring

VAERS
 Vaccine Adverse Event Reporting System

Co-managed by CDC and FDA
<http://vaers.hhs.gov>

Vaccine Adverse Event Reporting System (VAERS)

<p>Strengths</p> <ul style="list-style-type: none"> ▪ National data ▪ Accepts reports from anyone ▪ Rapidly detects safety signals ▪ Can detect rare adverse events ▪ Data available to public 	<p>Limitations</p> <ul style="list-style-type: none"> ▪ Reporting bias ▪ Inconsistent data quality and completeness ▪ Lack of unvaccinated comparison group ▪ Generally cannot assess causality
--	--

- VAERS is a spontaneous reporting (passive surveillance) system
- VAERS accepts all reports from all reporters without making judgments on causality or judging clinical seriousness of the event
- As a hypothesis generating system, VAERS identifies potential vaccine safety concerns that can be studied in more robust data systems

CDC

Vaccine safety monitoring

VSD
Vaccine Safety Datalink

8 participating integrated healthcare organizations

7

Vaccine Safety Datalink (VSD)


- Established in 1990
- Collaboration between CDC and several integrated healthcare plans
- Medical care and demographic data on over 12.1 million persons per year (~3.7% of U.S. population)
- Links vaccination data to health outcome data
- Used for surveillance (active) and research

8

VSD methods for surveillance and research

- Near real-time surveillance (Rapid Cycle Analysis [RCA])
- Traditional epidemiologic studies – observational designs; can be planned safety studies and studies to follow up on statistical signals detected in RCA
 - Cohort
 - Case-control
 - Self-controlled
 - Case only

9



CDC Vaccine safety monitoring

CISA Clinical Immunization Safety Assessment

7 participating medical research centers*

*Boston Medical Center, MA; Cincinnati Children's Hospital Medical Center, OH; Columbia University, NY; Duke University, NC; Johns Hopkins University, MD; Kaiser Permanente Northern California, CA; Vanderbilt University TN


vaccine safety experts

- assist U.S. healthcare providers with complex vaccine safety questions about their patients CISAeval@cdc.gov[†]
- conduct clinical research

[†]More information about clinical consults available at <http://www.cdc.gov/vaccines/imz/downloads/CISA.html>

CISA sites

- Boston Medical Center
- Cincinnati Children's Hospital Medical Center
- Columbia University
- Duke Clinical Research Institute
- Johns Hopkins University
- Kaiser Permanente Northern California
- Vanderbilt Medical Center



CDC Center for Disease Control and Prevention

Vaccine Safety

Ensuring Safety - Ensuring Safety - Vaccine Safety Monitoring - CISA

CISA Evaluation

Vaccine Safety Monitoring

Information for Healthcare Providers

Historical Background 2009-13

Evaluation Publications

Current Studies Technical Reports

Research

CISAeval@cdc.gov

If you are a US healthcare provider with a vaccine safety question about a specific patient needing care for that to not be fully resolved by relevant state or local health department resources, please contact your state health department and you will be expertly supported, you can contact CDC at CISAeval@cdc.gov if you need a CDC evaluation. This service is provided free of charge.

CDC's Immunization Safety Office (ISO) receives requests from US healthcare providers for consultation to address vaccine safety questions regarding patients residing in the US. CDC will determine whether this inquiry should be forwarded to CISA for an in-depth evaluation.

- Only selected requests will be forwarded for a CISA evaluation.
- Requests will be handled usually within 2 weeks after submission of a request. If the case will be reviewed by CISA.
- If the question is not forwarded for a CISA evaluation, then CDC will address the question or send it to another appropriate channel for a response.
- There is no cost to the provider for a CISA evaluation.

As soon as CDC/CISA requests to assist in determining whether they provide direct patient management, patient management decisions and the responsibility of the treating healthcare provider. CISA might require up to three months to collect and review all pertinent medical records, review the medical literature, review vaccine safety surveillance reports for other reports of adverse events, and discuss the case on a virtual consultation call with CISA members and the patient's healthcare provider if your patient is experiencing a medical emergency call 911 or your local emergency services provider.

To request a CISA evaluation, please provide your name, health professional licensing category (e.g., MD, DO, MD, PA, NP), and your contact information (phone number, email address, and professional affiliation).

Get Email Updates

CDC activities around SIRVA

- Joint review (with HRSA) of SIRVA injury claims to the National Vaccine Injury Compensation Program (VICP)
 - **In progress**
- VAERS review of reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine (IIV)
 - Reports with signs and symptoms that could be indicative of shoulder injuries following IIV are **uncommon and do not appear to be increasing** over time
- VSD study of risk of deltoid bursitis following IIV
 - Incidence is **uncommon, adult** condition, preliminary results indicate attributable risk of ~2.5 additional cases/million influenza vaccines administered
- Education and outreach on proper vaccine administration and SIRVA prevention

YOU CALL THE SHOTS

Shoulder injuries related to vaccine administration (SIRVA) occur because of improper vaccine administration (IIV) that result in shoulder injury (SI) or shoulder bursitis (SB) and tendinitis.

Make sure vaccination is safe.

KNOW THE SITE, GET IT RIGHT!

When administering vaccine by an intramuscular (IM) injection to an adult:

1. Use the correct syringe and needle.
2. Vaccinate by intramuscular (IM) injection either in the 1, 2, or 3rd, 4th, 5th, or 6th, 7th, 8th, 9th, 10th, 11th, or 12th, 13th, 14th, 15th, 16th, 17th, 18th, 19th, 20th, 21st, 22nd, 23rd, 24th, 25th, 26th, 27th, 28th, 29th, 30th, 31st, 32nd, 33rd, 34th, 35th, 36th, 37th, 38th, 39th, 40th, 41st, 42nd, 43rd, 44th, 45th, 46th, 47th, 48th, 49th, 50th, 51st, 52nd, 53rd, 54th, 55th, 56th, 57th, 58th, 59th, 60th, 61st, 62nd, 63rd, 64th, 65th, 66th, 67th, 68th, 69th, 70th, 71st, 72nd, 73rd, 74th, 75th, 76th, 77th, 78th, 79th, 80th, 81st, 82nd, 83rd, 84th, 85th, 86th, 87th, 88th, 89th, 90th, 91st, 92nd, 93rd, 94th, 95th, 96th, 97th, 98th, 99th, 100th.
3. Use the correct needle size based on your patient's size.
4. Inject the intramuscular injection site.

Identify the injection site

1. Locate the deltoid muscle of the upper arm.
2. Use anatomical landmarks to determine the injection site.
3. In adults, the midpoint of the deltoid is about 2 inches (5.1 cm) superior to the acromion process (bony prominence) and above the armpit in the middle of the upper arm.

Administer the vaccine correctly

1. Pinch the vaccine in the middle and middle part of the deltoid muscle.
2. Insert the needle at a 90° angle and inject all of the vaccine into the muscle tissue.

Always follow safe injection practices

- Perform aseptic technique
- Perform hand hygiene before preparing and administering vaccine
- Use a new needle and new syringe for each injection
- If using a single-use pre-filled syringe after use, it should be used for one patient only

Injection best practices

- Administering the vaccine too high on the upper arm may cause shoulder injury
- If administering additional vaccines into the same arm, separate the injection sites by 1 inch if possible

Report any clinically significant adverse event after vaccination to the Vaccine Adverse Event Reporting System (VAERS) if applicable.

For additional information on proper vaccine administration, visit the CDC vaccine administration web site at www.cdc.gov/vaccines/imz/downloads/infant.pdf

17

Injection Safety Errors during Immunization

- Frequent
- Completely preventable
- Significant negative outcomes for patients

Employee Influenza Vaccination Clinic, 2015


- NJ DoH notified used syringes reused at employee influenza vaccination clinic
 - Out-of-state health services company
 - Nurse arrived with 3 multi-dose vials instead of prefilled syringes specified
- Nurse reported using two syringes to inject 67 employees
- Urgent Public Health response included bloodborne pathogen testing, counseling and offers to revaccinate

Injection Safety and Vaccine Administration Errors at an Employee Influenza Vaccination Clinic — New Jersey, 2015

Learn More: P03, Rebecca Grady, MPH, JD, Chris Guo, MPH, Nicole Russo, MPH, JD, Susan, MPH, Jodie Hirsch, MPH, Joseph Kim, DPH, Christine Yu, MD, Stephen Williams, MD, DDCO@NJDOH | Morbidity and Mortality Weekly Report, 2015;44(8):553-554.

On September 30, 2015, the New Jersey Department of Health (NJDOH) was notified by an out-of-state health services company that an inexperienced nurse had reused syringes for multiple persons earlier that day. This occurred at an

Colorado Pediatric Clinic, April 2011 Patient Notification due to Syringe Reuse



- ❑ Medical assistant administered flu vaccine from one syringe to multiple patients
 - Children between age 6 months and 35 months put at risk
- ❑ Patient notification conducted; bloodborne pathogen testing advised

April 12, 2011

Children told to be tested for HIV after flu vaccines reused

10/19/11, April 12, 2011 | 171 views

FOX 59 NEWS VIDEOS MORNING TRAFFIC COMMUNITY CONTESTS PODCASTS ON-AIR TEAM SPORTS WEATHER 74°

Officials warn vaccinations given in Indiana, Kentucky and Ohio may be causing infections

POSTED 1:29 PM, FEBRUARY 2, 2018, BY FOX59WEB, UPDATED AT 6:54PM, FEBRUARY 2, 2018

FRANKFORT, Ky. – Health officials say vaccinations given out at various businesses in Indiana, Kentucky and Ohio may be causing infections because of contamination. Kentucky's Department of Public Health (DPH) said Friday that the provider "Location Vaccination" had been giving the vaccinations at businesses since Sept. 1, 2018...

...multiple people have developed infections associated with the vaccines and those infected have experienced redness, pain or tenderness, swelling, and the development of hard lumps, or nodules, at the injection site.

